Navigation Links
New Target for Muscular Dystrophy Drug Therapy Discovered

Researchers at the University of Pennsylvania School of Medicine have discovered a new target for the muscular dystrophy drug therapy .

The researchers have found how the gene for utrophin-which codes for a protein very similar to dystrophin, the defective protein in Duchenne muscular dystrophy (DMD)-puts the brakes on its own expression in muscle cells.

The production of utrophin slows in foetal muscles soon after birth, following which dystrophin takes over as the primary muscle-associated protein. How this normal utrophin silencing occurs has been a mystery for long, according to the background information in an article published online in Molecular Biology of the Cell.

Dr. Tejvir S. Khurana, Associate Professor of Physiology and Member of the Pennsylvania Muscle Institute, says the removal of silencing by drug intervention may help increase utrophin expression, which in turn may substitute for dystrophin as a possible therapy for DMD.

Experiments on mice have now shown that utrophin silencing is applied by a protein called Ets-2 repressor factor (ERF) sitting on a small piece of the utrophin gene called the N-box.

"We demonstrated that ERF significantly reduces or represses the activity of utrophin's N-box in muscle cells of mice," says Dr. Tejvir S. Khurana, 7senior author of the study.

During the study, the researchers noted that ERF did not have any effect on utrophin silencing when the N-box was deleted from the utrophin gene. They also observed that utophin mRNA production increased when ERF was repressed.

"This approach of 'repressing the repressor' is medically relevant to treating muscular dystrophy in that we hope to one day be able to upregulate utrophin production," explains Dr. Khurana.

Since the gene sequence of utrophin is over 80 per cent identical to that of dystrophin, it may substitute for dystrophin in muscle cells, says resea rchers.

Dr. Khurana, however, wants to ensure first whether repressing ERF reduces muscle deterioration in mice or not.

"We have worked on this problem for a number of years, and our current findings are a logical incremental step in understanding how utrophin could become an effective tool for treating DMD," states Dr. Khurana.


'"/>




Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Target of diabetes type 1 identified
6. Gene Target For Tuberculosis Identified
7. New Vaccine Targeted At Effective Treatment Against Tuberculosis
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
10. Doctors, Pharma Companies Targeted By CBI Raids
11. Research Targets treatment for dementia and brain injuries
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: